although
respiratori
syncyti
viru
rsv
infect
often
present
selflimit
upper
respiratori
tract
infect
urti
healthi
adult
immunocompromis
patient
higher
rate
progress
urti
lower
respiratori
tract
infect
lrti
mortal
rate
associ
lrti
high
hematopoiet
stem
cell
transplant
hsct
recipi
lung
transplant
infect
commun
respiratori
virus
includ
rsv
associ
develop
bronchiol
obliteran
syndrom
mortal
rate
rsv
infect
popul
report
high
ribavirin
rbv
intraven
immunoglobulin
ivig
use
treatment
rsv
infect
despit
absenc
larg
prospect
random
control
trial
demonstr
efficaci
treatment
adult
immunocompromis
patient
nonrandom
data
suggest
howev
inhal
oral
rbv
may
reduc
progress
urti
lrti
reduc
mortal
agent
signific
limit
includ
high
cost
poor
toler
potenti
toxic
moreov
guidelin
exist
treatment
rsv
immunocompromis
adult
absenc
clear
evid
given
potenti
drawback
avail
treatment
sought
assess
larg
transplant
center
manag
rsv
well
noninfluenza
respiratori
viral
infect
immunocompromis
adult
midwestern
respiratori
viru
collabor
mrvc
cooper
effort
among
larg
midwestern
transplant
center
studi
respiratori
viru
infect
transplant
patient
survey
see
supplementari
data
design
gather
descript
inform
center
includ
follow
center
size
number
adult
stem
cell
transplant
perform
type
solid
organ
transplant
sot
perform
diagnost
method
respiratori
viral
infect
avail
inhal
rbv
dose
interv
use
inhal
oral
rbv
institut
number
adult
sot
perform
institut
obtain
optntransplanthrsagov
also
assess
use
ivig
product
survey
gather
inform
regard
usual
treatment
practic
rsv
urti
lrti
follow
scenario
preengraft
autolog
allogen
hsct
recipi
postengraft
autolog
hsct
recipi
within
month
transplant
postengraft
autolog
hsct
recipi
month
transplant
postengraft
allogen
hsct
recipi
without
graftversushost
diseas
gvhd
month
transplant
allogen
hsct
recipi
without
gvhd
month
transplant
lung
transplant
recipi
nonlung
sot
recipi
patient
hematolog
malign
addit
ask
manag
noninfluenza
nonrsv
respiratori
virus
parainfluenza
human
metapneumoviru
coronaviru
adenoviru
includ
prefer
treatment
popul
would
routin
treat
descript
statist
present
survey
sent
via
email
transplant
infecti
diseas
physician
transplant
center
particip
mrvc
twelv
center
respond
characterist
tabl
center
use
multiplex
polymeras
chain
reaction
pcr
diagnosi
respiratori
viral
infect
use
pcr
immunocompromis
patient
limit
use
inpati
set
one
center
primarili
use
rapid
antigen
test
diagnosi
tabl
describ
rbv
usag
dose
treatment
rsv
infect
inhal
rbv
use
outpati
center
use
inpati
center
center
use
inhal
rbv
reason
includ
cost
inconveni
safeti
concern
regard
teratogen
lack
efficaci
three
state
specif
prefer
oral
rbv
six
center
use
oral
inhal
rbv
depend
clinic
situat
preferenti
util
inhal
rbv
remain
util
inhal
oral
rbv
casebycas
andor
servicespecif
basi
one
center
note
inhal
rbv
use
sever
case
one
center
routin
use
inhal
oral
rbv
use
ivig
monotherapi
circumst
center
use
ivig
given
combin
inhal
oral
rbv
ivig
use
treatment
urti
center
center
use
ivig
case
patient
hypogammaglobulinem
center
use
palivizumab
center
report
followup
commun
palivizumab
expens
use
adult
patient
likewis
variat
found
manag
strategi
patient
popul
fig
treatment
strategi
exclud
center
manag
depend
symptom
hsct
recipi
lrti
gvhd
recent
transplant
like
receiv
antivir
treatment
inhal
rbv
use
higher
rate
oral
rbv
center
experi
lung
transplant
treat
lrti
patient
either
oral
inhal
rbv
one
center
use
prednison
combin
rbv
one
center
use
inhal
rbv
treat
urti
patient
hematolog
malign
urti
otherwis
typic
treat
group
nonlung
sot
patient
treatment
lrti
popul
describ
figur
survey
recipi
also
ask
manag
noninfluenza
nonrsv
respiratori
virus
three
center
treat
sever
parainfluenza
metapneumoviru
treat
coronaviru
treatment
includ
rbv
ivig
investig
drug
parainfluenza
infect
center
would
treat
lrti
dissemin
adenoviru
infect
intraven
cidofovir
investig
agent
avail
knowledg
first
survey
document
manag
strategi
rsv
infect
adult
immunocompromis
patient
absenc
strong
evid
effect
particular
treatment
surpris
treatment
strategi
differ
wide
among
center
consensu
exist
regard
manag
trend
observ
diagnost
strategi
uniform
aspect
manag
center
util
multiplex
pcr
provid
sever
potenti
advantag
tradit
diagnost
method
includ
rapid
turnaround
time
capabl
identifi
multipl
respiratori
pathogen
addit
pcr
appear
sensit
cultur
antigen
test
treatment
strategi
vari
significantli
center
center
aspect
treatment
fundament
dose
frequenc
rout
administr
rbv
wide
rang
oral
rbv
dose
rang
mg
daili
refer
recommend
dose
hepat
c
viru
rang
mg
daili
weightbas
dose
oral
rbv
rsv
therapi
offlabel
use
littl
inform
avail
defin
appropri
dose
avail
literatur
dose
strategi
vari
includ
nonweightbas
weightbas
regimen
rang
typic
mg
kgday
mgkgday
inhal
rbv
approv
use
children
dose
g
aerosol
h
long
durat
nebul
difficult
toler
often
disrupt
patient
care
activ
limit
data
suggest
intermitt
dose
schedul
equal
term
safeti
may
superior
prevent
progress
lrti
altern
intermitt
dose
schedul
g
aerosol
everi
h
typic
period
administr
commonli
use
regimen
survey
inhal
rbv
use
frequent
oral
scenario
present
particularli
scenario
involv
lrti
avail
treatment
inhal
rbv
studi
systemat
review
suggest
benefit
term
decreas
progress
lrti
mortal
administr
inhal
rbv
plu
monoclon
palivizumab
polyclon
antibodi
prepar
ivig
rsvivig
retrospect
studi
hsct
popul
shown
similar
result
evid
efficaci
oral
rbv
limit
howev
retrospect
studi
suggest
well
toler
hsct
lung
transplant
recipi
systemat
review
note
oral
rbv
combin
ivig
andor
palivizumab
associ
lower
rate
progress
lrti
mortal
although
effect
pronounc
seen
inhal
rbv
combin
immunomodul
ivig
rsvivig
andor
palivizumab
note
rsvivig
longer
commerci
avail
studi
aim
determin
efficaci
rsvivig
prophylaxi
rsv
infect
allogen
hsct
recipi
unabl
determin
benefit
likewis
palivizumab
costli
proven
efficaci
prevent
progress
urti
lrti
reduc
mortal
adult
allogen
hsct
recipi
center
less
like
treat
urti
despit
avail
evid
treatment
urti
stage
prevent
progress
lrti
inhal
rbv
main
limit
outpati
administr
includ
cost
treatment
cours
inhal
rbv
typic
cost
compar
cours
oral
rbv
difficulti
administr
tent
necessari
concern
environment
contamin
potenti
teratogen
healthcar
worker
lung
transplant
patient
highest
rate
treatment
urti
stage
patient
popul
unanim
exist
regard
decis
treat
lrti
multidrug
regimen
inhal
rbv
ivig
corticosteroid
palivizumab
show
efficaci
maintain
allograft
function
rsv
infect
furthermor
studi
evalu
use
oral
rbv
suggest
equival
inhal
rbv
treatment
rsv
lung
transplant
nonlung
sot
patient
hematolog
malign
center
would
treat
urti
consist
infecti
diseas
societi
america
guidelin
recommend
routin
treatment
rsv
urti
neutropen
patient
lrti
treat
higher
rate
howev
studi
evalu
incid
spectrum
rsv
infect
popul
scarc
studi
number
limit
data
collect
via
survey
form
possibl
recal
bia
exist
institut
without
set
protocol
treatment
strategi
may
vari
treat
physician
addit
survey
institut
locat
midwest
region
differ
manag
may
exist
survey
appar
treatment
strategi
vari
greatli
among
institut
although
mani
center
treat
lrti
treatment
urti
variabl
inhal
rbv
use
commonli
consensu
exist
regard
use
compar
oral
rbv
regard
use
ivig
given
potenti
sever
rsv
infect
adult
immunocompromis
patient
variabl
demonstr
critic
need
welldesign
studi
examin
current
use
novel
agent
attempt
random
studi
examin
efficaci
inhal
rbv
past
success
owe
poor
enrol
perhap
reluct
accept
placebo
arm
would
advoc
repeat
effort
larger
multicent
nonintervent
trial
could
better
identifi
risk
factor
poor
outcom
identifi
popul
like
benefit
expens
potenti
toxic
therapi
inhal
oral
rbv
issu
howev
may
solv
new
therapi
test
approv
topic
administ
small
interf
rna
oral
fusion
inhibitor
inhal
viral
fusion
inhibitor
variou
stage
develop
provid
hope
proven
effect
treatment
soon
avail
present
studi
provid
insight
current
practic
larg
transplant
center
